Hibiscus

1. What conditions has Hibiscus been studied for?

• Hypertension (high blood pressure): Multiple randomized controlled trials (RCTs) and a meta-analysis evaluated Hibiscus sabdariffa (roselle) tea/extract for systolic and diastolic blood pressure reduction.

• Dyslipidemia / hyperlipidemia (cholesterol and triglycerides): RCTs and animal studies assessed effects on total cholesterol, LDL-C, triglycerides, and sometimes HDL-C.

• Type 2 diabetes / hyperglycemia: Clinical and preclinical evidence is cited for antihyperglycemic effects; mechanisms proposed include inhibition of α-glucosidase and α-amylase and vascular endothelial protection (network pharmacology + experimental validation).

• Kidney and liver-related outcomes: Reviews describe nephroprotective and hepatoprotective effects (mostly preclinical), plus diuretic/renal effects.

• Oxidative stress and inflammation-related conditions: Reviews emphasize antioxidant activity and potential relevance to chronic/degenerative diseases associated with oxidative stress.

• Antimicrobial activity: In vitro antibacterial activity is reported for H. sabdariffa; a broader edible-flower study also assessed antimicrobial activity across flowers (not hibiscus-specific in the provided excerpt).

• Body composition/weight-related outcomes: A clinical-trial narrative review lists “body fat mass reduction” among reported outcomes for H. sabdariffa preparations.

• Other indications (primarily traditional use / preclinical, especially for Hibiscus rosa-sinensis): Reviews list antimicrobial, antioxidant, antidiabetic, anti-inflammatory, antihypertensive, antifertility, antifungal, anticancer, hair growth-promoting, antihyperlipidemic, reproductive, neurobehavioral, antidepressant, and antipyretic activities (largely not supported by RCT evidence in the studies reviewed here).

• Diabetes in animal models for other Hibiscus species: Hibiscus trionum was studied in diabetes-induced rats for glycemic control, oxidative stress enzymes, lipid peroxidation, lipids, and liver enzymes.

2. Does it work in treating those conditions? Summarize the evidence.

• Hypertension: The strongest human evidence in the studies is for Hibiscus sabdariffa lowering blood pressure.

  • A systematic review/meta-analysis of 5 RCTs (7 treatment arms; 390 participants) found significant reductions vs control: SBP −7.58 mmHg (95% CI −9.69 to −5.46) and DBP −3.53 mmHg (95% CI −5.16 to −1.89). Effects were inversely associated with baseline BP (greater reductions when baseline BP was higher).

  • A broader RCT-focused review states that daily HS tea/extract significantly lowered SBP and DBP in adults with pre- to moderate essential hypertension and in type 2 diabetes; it also reports HS tea was as effective as captopril but less effective than lisinopril in some comparisons.

  • Limitations noted across reviews: many studies use poorly characterized extracts and more well-designed, standardized trials are needed.

• Dyslipidemia (cholesterol/triglycerides): Evidence is mixed-to-moderately supportive.

  • The cardiovascular risk-factor review reports that in animal models HS generally lowered total cholesterol, LDL-C, and triglycerides, while HDL-C was usually unchanged.

  • In human RCTs, the same review reports over half showed favorable lipid changes (reductions in total cholesterol, LDL-C, triglycerides, and sometimes increased HDL-C), implying inconsistency across trials.

  • Overall: promising but not uniformly positive; standardization and higher-quality trials are repeatedly requested.

• Diabetes / hyperglycemia: Evidence exists but is less clearly established in the studies reviewed here than for blood pressure.

  • Reviews cite anti-diabetic effects and propose mechanisms (e.g., α-glucosidase and α-amylase inhibition), and a 2019 mechanistic study suggests vascular endothelial protection using network pharmacology plus experimental validation.

  • However, the studies reviewed here do not quantify pooled glucose/HbA1c effects from RCTs; the clinical evidence base is described as needing better-designed trials and standardized preparations.

  • For other species: Hibiscus trionum shows investigation in diabetic rats (preclinical only), which cannot establish clinical efficacy.

• Kidney/liver protection and diuresis: Mostly preclinical and narrative clinical reporting.

  • Reviews describe nephro- and hepato-protective effects and a diuretic/renal effect; one review notes diuretic action with electrolytes usually not significantly affected in most cases.

  • Clinical-trial narrative review lists nephroprotective and anti-inflammatory/antioxidant outcomes, but the studies do not provide effect sizes or trial counts for these endpoints.

• Antimicrobial/antioxidant effects: Supported mainly by in vitro assays and compositional studies; clinical relevance is not established in the studies.

3. What health benefits does it have?

Based on the studies, the most consistently supported benefits relate to cardiovascular risk factors, with additional potential metabolic and antioxidant-related effects.

• Blood pressure reduction: RCT meta-analysis evidence supports clinically meaningful average reductions in SBP and DBP with H. sabdariffa supplementation.

• Potential lipid profile improvement: Many (but not all) RCTs report improvements in total cholesterol, LDL-C, triglycerides, and sometimes HDL-C.

• Antioxidant activity: Reviews attribute multiple effects to strong antioxidant activity; anthocyanins and other polyphenols are emphasized.

• Potential glycemic benefits: Reported anti-diabetic/antihyperglycemic activity with proposed enzyme inhibition (α-glucosidase/α-amylase) and possible endothelial protection mechanisms.

• Diuretic/renal effects: Evidence suggests a diuretic effect, generally without major electrolyte disturbances in most cases described.

• Possible liver/kidney protective effects: Nephroprotective and hepatoprotective effects are described (largely preclinical; some clinical-trial narratives mention nephroprotective outcomes).

• Anti-inflammatory and other reported clinical-trial outcomes: A narrative review lists antioxidant, anti-inflammatory, antianemic, body fat mass reduction, and anti-xerostomic activities for HS preparations, though details and consistency are not provided in the studies.

Compounds proposed to contribute include anthocyanins (e.g., delphinidin-3-sambubioside, cyanidin-3-sambubioside), phenolic acids (especially protocatechuic acid), and organic acids (hibiscus acid, hydroxycitric acid). Proposed mechanisms include ACE inhibition, direct vasorelaxation or calcium channel modulation, antioxidant effects, and inhibition of carbohydrate-digesting enzymes.

4. Does it have any downsides or side effects?

• Overall tolerability appears good in the studies reviewed here:

  • One review states H. sabdariffa has an “excellent safety and tolerability record.”

  • The cardiovascular review notes traditional use in at least 10 countries for hypertension/hyperlipidemia with no reported adverse events or side effects in that context.

  • A narrative review of clinical trials reports no adverse effects during the trials summarized.

• Toxicology signals and cautions:

  • The cardiovascular review reports low acute toxicity in animals with an LD50 ~2,000 to >5,000 mg/kg/day (extract-dependent).

  • It also states there is no evidence of hepatic or renal toxicity from HS extract consumption, except possible adverse hepatic effects at high doses.

  • Diuretic effect: HS may act as a diuretic; most cases reported no significant electrolyte changes, but this remains a plausible monitoring consideration, especially in people on diuretics or with kidney disease (the studies do not provide interaction data).

• Quality/standardization downside: Multiple reviews emphasize that many studies used phytochemically poorly characterized extracts and call for standardized “fingerprints” for quality control; variability in preparations is a practical downside affecting predictability of effects.

Important limitation: the studies reviewed here do not detail rates of specific side effects (e.g., GI symptoms) or drug–herb interactions; absence of reported adverse events in trials does not guarantee absence of risk, especially with higher doses, long-term use, or concentrated extracts.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings (no genotype-stratified outcomes, no variant-specific efficacy/toxicity, and no gene–compound interaction data).

• No evidence in these studies that Hibiscus effects differ by genetic variants (e.g., ACE gene polymorphisms, drug-metabolizing enzymes, transporters).

• Mechanistic relevance is plausible but unproven here: because proposed mechanisms include ACE inhibition and possible calcium channel modulation, genetic variation in related pathways could theoretically influence response, but this is not tested or demonstrated in the provided material.

References

1. Hibiscus sabdariffa L. - a phytochemical and pharmacological review.
   Inês Da-Costa-Rocha, Bernd Bonnlaender, Hartwig Sievers, Ivo Pischel, Michael Heinrich (2014) - Food chemistry
2. A review on phytochemistry and therapeutic uses of Hibiscus sabdariffa L.
   Ghazala Riaz, Rajni Chopra (2018) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
3. Functional, Antioxidant, Antibacterial, and Antifungal Activity of Edible Flowers.
   Elena Coyago-Cruz, Alejandro Alarcón, Aida Guachamin, Gabriela Méndez, Edison Osorio, Jorge Heredia-Moya, Johana Zuñiga-Miranda, Elena Beltrán-Sinchiguano, Edwin Vera (2024) - Antioxidants (Basel, Switzerland)
4. Herbal Teas and their Health Benefits: A Scoping Review.
   Fatima S Poswal, Grace Russell, Marion Mackonochie, Euan MacLennan, Emmanuel C Adukwu, Vivien Rolfe (2019) - Plant foods for human nutrition (Dordrecht, Netherlands)
5. Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies.
   Allison L Hopkins, Marnie G Lamm, Janet L Funk, Cheryl Ritenbaugh (2013) - Fitoterapia
6. Organic Acids from Roselle (
   Jeannett A Izquierdo-Vega, Diego A Arteaga-Badillo, Manuel Sánchez-Gutiérrez, José A Morales-González, Nancy Vargas-Mendoza, Carlos A Gómez-Aldapa, Javier Castro-Rosas, Luis Delgado-Olivares, Eduardo Madrigal-Bujaidar, Eduardo Madrigal-Santillán (2020) - Biomedicines
7. Network pharmacology-based analysis of the anti-hyperglycemic active ingredients of roselle and experimental validation.
   Bingxuan Niu, Xu Xie, Xiaoming Xiong, Junlin Jiang (2022) - Computers in biology and medicine
8. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials.
   Corina Serban, Amirhossein Sahebkar, Sorin Ursoniu, Florina Andrica, Maciej Banach (2015) - Journal of hypertension
9. Physiological Effects and Human Health Benefits ofHibiscus sabdariffa: A Review of Clinical Trials
   Efigenia Montalvo-González, Zuamí Villagrán, Sughey González-Torres, Laura Elena Iñiguez-Muñoz, Mario Alberto Isiordia-Espinoza (2022)
10. Therapeutic potentials of Hibiscus trionum: Antioxidant, anti-lipid peroxidative, hypoglycemic, and hepatoprotective effects in type 1 diabetic rats.
    Sedef Ziyanok-Demirtas (2024) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
11. Medicinal plants with anti-colorectal cancer bioactive compounds: Potential game-changers in colorectal cancer management.
    John M Macharia, Ruth W Mwangi, Nora Rozmann, Kaposztas Zsolt, Tímea Varjas, Paschal O Uchechukwu, Isabel N Wagara, Bence L Raposa (2022) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
12. Beneficial Effects of Natural Bioactive Compounds from
    Oyindamola Vivian Ojulari, Seul Gi Lee, Ju-Ock Nam (2019) - Molecules (Basel, Switzerland)
13. The Potential of Roselle (Hibiscus sabdariffa) Plant in Industrial Applications: A Promising Source of Functional Compounds.
    Lye Yee Chew, Suk Kuan Teng, Yun Ping Neo, Yan Yi Sim, Sook Chin Chew (2024) - Journal of oleo science
14. Medicinal herbs, especially Hibiscus sabdariffa, inhibit oral pathogenic bacteria.
    Kazuya Takada, Shizuki Nakano, Reina Nishio, Daichi Muku, Shinichi Mochizuki, Inori Inui, Kaede Okita, Ayaka Koga, Koji Watanabe, Yoshie Yoshioka, Wataru Ariyoshi, Ryota Yamasaki (2024) - Journal of oral biosciences
15. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
    Cristina Belizna, Francesca Pregnolato, Sebastien Abad, Jaume Alijotas-Reig, Howard Amital, Zahir Amoura, Laura Andreoli, Emmanuel Andres, Achile Aouba, Sule Apras Bilgen, Laurent Arnaud, Boris Bienvenu, Viktoria Bitsadze, Patrick Blanco, Miri Blank, Maria Orietta Borghi, Antonia Caligaro, Elisabeta Candrea, Valentina Canti, Laurent Chiche, Jean Marie Chretien, Jan Willem Cohen Tervaert, Laura Damian, Teresa Delross, Emmanuelle Dernis, Katrien Devreese, Aleksandra Djokovic, Enrique Esteve-Valverde, Maria Favaro, Céline Fassot, Raquel Ferrer-Oliveras, Alban Godon, Mohamed Hamidou, Milena Hasan, Daniel Henrion, Bernard Imbert, Pierre Yves Jeandel, Pascale Jeannin, Patrick Jego, Noemie Jourde-Chiche, Jamilya Khizroeva, Olivier Lambotte, Cédric Landron, Jose Omar Latino, Estibaliz Lazaro, Karina de Leeuw, Thomas Le Gallou, Levent Kiliç, Maarten Limper, Laurent Loufrani, Romain Lubin, Nadine Magy-Bertrand, Guillaume Mahe, Alexander Makatsariya, Thierry Martin, Christian Muchardt, Gyorgy Nagy, Loukman Omarjee, Pieter Van Paasen, Gilles Pernod, Florence Perrinet, Gilberto Pïres Rosa, Marc Antoine Pistorius, Amelia Ruffatti, Fatma Said, Patrick Saulnier, Damien Sene, Loic Sentilhes, Ova Shovman, Jean Sibilia, Crina Sinescu, Natasa Stanisavljevic, Ljudmila Stojanovich, Lai Shan Tam, Angela Tincani, Fréderic Tollis, Sebastian Udry, Marie Noelle Ungeheuer, Mathilde Versini, Ricard Cervera, Pier Luigi Meroni (2018) - Autoimmunity reviews
16. Isolation and Characterization of Anthocyanins from Hibiscus sabdariffa Flowers.
    Claudia Grajeda-Iglesias, Maria C Figueroa-Espinoza, Nathalie Barouh, Bruno Baréa, Ana Fernandes, Victor de Freitas, Erika Salas (2016) - Journal of natural products
17. Hibiscus and lemon verbena polyphenols modulate appetite-related biomarkers in overweight subjects: a randomized controlled trial.
    Marina Boix-Castejón, María Herranz-López, Alberto Pérez Gago, Mariló Olivares-Vicente, Nuria Caturla, Enrique Roche, Vicente Micol (2018) - Food & function
18. Wound healing effect of polydeoxyribonucleotide derived from Hibiscus sabdariffa callus via Nrf2 signaling in human keratinocytes.
    Euihyun Kim, Sunmee Choi, Soo-Yun Kim, Sung Joo Jang, Sak Lee, Hyein Kim, Ji Hyeon Jang, Hyo Hyun Seo, Jeong Hun Lee, Sung Soo Choi, Sang Hyun Moh (2024) - Biochemical and biophysical research communications

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.